Royal Bank of Canada lowered its stake in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 88.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 51,858 shares of the company’s stock after selling 393,734 shares during the quarter. Royal Bank of Canada owned 0.12% of ARK Genomic Revolution ETF worth $1,369,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ARKG. NewEdge Advisors LLC boosted its holdings in ARK Genomic Revolution ETF by 49.4% in the 1st quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock worth $112,000 after buying an additional 1,780 shares during the last quarter. Creative Planning purchased a new position in shares of ARK Genomic Revolution ETF in the second quarter valued at approximately $255,000. Baird Financial Group Inc. lifted its position in shares of ARK Genomic Revolution ETF by 81.0% in the second quarter. Baird Financial Group Inc. now owns 71,977 shares of the company’s stock valued at $1,753,000 after acquiring an additional 32,221 shares in the last quarter. Strategic Wealth Investment Group LLC acquired a new stake in shares of ARK Genomic Revolution ETF in the second quarter worth approximately $38,000. Finally, Group One Trading LLC acquired a new stake in shares of ARK Genomic Revolution ETF in the second quarter worth approximately $2,274,000.
ARK Genomic Revolution ETF Stock Up 10.5%
Shares of ARKG opened at $47.73 on Thursday. ARK Genomic Revolution ETF has a 52-week low of $23.42 and a 52-week high of $47.73. The firm’s fifty day moving average is $40.24 and its two-hundred day moving average is $33.17.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
